All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet (R) International Outcome Study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375260" target="_blank" >RIV/00216208:11130/18:10375260 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064203:_____/18:10375260

  • Result on the web

    <a href="https://doi.org/10.1515/jpem-2017-0489" target="_blank" >https://doi.org/10.1515/jpem-2017-0489</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1515/jpem-2017-0489" target="_blank" >10.1515/jpem-2017-0489</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet (R) International Outcome Study

  • Original language description

    Background: We investigated time trends in age, gender, growth hormone (GH) dose and height standard deviation score (SDS) in children with GH deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) starting GH treatment. Methods: Data were obtained from children enrolled in the NordiNet (R) International Outcome Study (IOS) between 2006 and 2015 in the Czech Republic, France, Germany, Serbia and Montenegro (all indications), and Switzerland and the UK (GHD only). Trends were analyzed by linear regression. Patients were divided by age into early-, medium-or late-start groups in three different time periods. Results: Approximately one-third of children starting treatment for GHD were girls, with no apparent increase in proportion over time. The mean baseline age for starting treatment decreased significantly (p &lt; 0.001) for both GHD and SGA in the Czech Republic and Germany. In the other countries studied, over 40% of children started treatment for GHD and SGA late (girls &gt;10, boys &gt;11 years) between 2013 and 2015. The mean baseline GH doses were largely within recommended ranges for GHD and SGA, but below the lowest recommended starting dose for TS in almost every year since 2011 except in France. Conclusions: Approximately one-third of children starting treatment for GHD were girls. Between 2013 and 2015, more than 40% of children started treatment for GHD and SGA late except in Germany and the Czech Republic. TS patients received below-recommended doses. These results highlight the need for earlier identification of short stature in children, particularly girls, and for dose optimization in TS.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30202 - Endocrinology and metabolism (including diabetes, hormones)

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Pediatric Endocrinology &amp; Metabolism

  • ISSN

    0334-018X

  • e-ISSN

  • Volume of the periodical

    31

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    12

  • Pages from-to

    521-532

  • UT code for WoS article

    000431124900006

  • EID of the result in the Scopus database

    2-s2.0-85045875005